There are vitamins such as Vitamin e that also inhibit leucotrienes
and ,soy milk isoflavones. If this product is really the answer for
us all then I would expect some reports from people who have had
success with other products that are inhibitory to the leucotriene
pathway. I dont see any so am concerned that this is raising false
hope. Id love to see a cure for this beast and I am doing my own
little experiment targeting the pathways and enzymes associated with
inflammation to help me. Can any others report on any success with
this approach. I kinda feel that it is too simple to be a cure as
this condition seems to be very complicated and caused by not one
but a number of contributing factors.




-- In rosacea-support@yahoogroups.com, "Dr. Geoffrey Nase, PhD"
<drnase1000@h...> wrote:
>
>
> Hello,
>
> I would definitely wait until they finish the phase III trials to
> determine if there are any side effects that patients might have
to
> consider.
>
> Geoffrey
> ______________________________
>
> Dr. Geoffrey Nase
> Ph.D. Neurovascular Physiologist
> http://www.drnase.com
> ______________________________
>
>
>
>
>
>
> > Zileutton is already in tthe market ?
> > Can we take it?
> >
> > --- "Dr. Geoffrey Nase, PhD" <drnase1000@h...>
> > escribió:
> > >
> > >
> > >
> > > Zieluton – More than an acne treatment
> > >
> > > Zileuton is now broadening its treatment indications
> > > for other
> > > inflammatory skin disorders including rosacea.
> > > Zileuton can be
> > > taken long term, has no harmful effect on
> > > non-asthmatics, reduces
> > > sebum by about 65%, shrinks sebaceous glands and
> > > decreases
> > > inflammatory lesions by about 75% in just 3 months.
> > >
> > > More importantly, Leukotriene B4 (which is the main
> > > substance
> > > blocked by zileuton) is (1) a strong dilator in the
> > > skin (patients
> > > report significant decreases in facial skin warmth
> > > while on the
> > > medication), (2) one of the most important initial
> > > causes of
> > > swelling, and (3) is one of the primary substances
> > > that binds to
> > > sensory nerve fibers in the facial skin to increase
> > > the sensation of
> > > pain and burning in the skin. Critical
> > > therapeutics, the makers of
> > > zileuton need to be made aware of the great promise
> > > this oral drug
> > > has for rosacea.
> > >
> > > Below is just an update on its actions on acne,
> > > sebum and
> > > inflammatory papules.
> > >
> > > Geoffrey
> > > ______________________________
> > >
> > > Dr. Geoffrey Nase
> > > Ph.D. Neurovascular Physiologist
> > > http://www.drnase.com
> > > ______________________________
> > >
> > >
> > >
> > >
> > > Critical Therapeutics to Begin Phase II Study of
> > > Zileuton for
> > > Moderate to Severe Acne
> > >
> > > Efficacy and Safety Trial to be Conducted in up to
> > > 90 Patients
> > >
> > > LEXINGTON, Mass., Oct. 5, 2004--Critical
> > > Therapeutics, Inc. (Nasdaq:
> > > CRTX ), a biopharmaceutical company focused on the
> > > discovery,
> > > development and commercialization of products for
> > > respiratory,
> > > inflammatory and critical care diseases, today
> > > announced that it
> > > will begin enrolling patients in a Phase II clinical
> > > study this
> > > month to assess the efficacy and safety of Zyflo®,
> > > the tablet
> > > formulation of zileuton, in patients with moderate
> > > to severe acne.
> > >
> > > "By focusing on the role of inflammatory mediators
> > > in the
> > > pathogenesis of acne, our goal is to identify new
> > > therapeutic
> > > approaches to treat a major factor in the
> > > progression of this
> > > disease," said the study's principal investigator,
> > > Diane M.
> > > Thiboutot, M.D., professor of dermatology at Penn
> > > State Milton S.
> > > Hershey Medical Center/Penn State University College
> > > of
> > > Medicine. "Today, patients with moderate to severe
> > > acne have limited
> > > treatment options, so there is an established need
> > > for treatment
> > > alternatives with the potential to help manage this
> > > disease."
> > >
> > > The double-blind, randomized, placebo-controlled
> > > Phase II study will
> > > consist of two groups of approximately 45 patients
> > > each, with the
> > > active drug group receiving Zyflo tablets for 12
> > > weeks. The 30-day
> > > waiting period related to the investigational new
> > > drug submission
> > > for this study ended September 16, 2004 and patient
> > > dosing is
> > > scheduled to begin this month at multiple centers in
> > > the United
> > > States. The study is expected to be completed in the
> > > first half of
> > > 2005. Acne affects approximately 17 million people
> > > in the United
> > > States, according to the American Academy of
> > > Dermatology. The
> > > leading branded therapy for acne generated peak
> > > sales in excess of
> > > $500 million despite carrying a restrictive label.
> > >
> > > Zyflo was approved by the U.S. Food and Drug
> > > Administration (FDA) in
> > > 1996 for the treatment of asthma in patients 12 and
> > > older. Zyflo
> > > blocks the activity of 5 lipoxygenase (5-LO), the
> > > enzyme chiefly
> > > responsible for producing a range of inflammatory
> > > mediators known as
> > > leukotrienes, which are believed to play a central
> > > role in tissue
> > > inflammation related to asthma, acne and other
> > > diseases.
> > >
> > > Leukotriene B4, which can be blocked by zileuton,
> > > has been shown to
> > > promote the production of skin surface oils known as
> > > sebum lipids.
> > > Key findings of a zileuton pilot study in acne
> > > included a 65% mean
> > > reduction of sebum lipids at 12 weeks (p=0.04) and a
> > > mean reduction
> > > in inflammatory lesions of 71% at 12 weeks
> > > (p=0.007). There was also
> > > a significant reduction in the acne severity index
> > > as early as 4
> > > weeks (p is less than 0.05). Results from this study
> > > were published
> > > in the May 2003 edition of the Archives of
> > > Dermatology.
> > >
> > > "The initiation of this trial is an important step
> > > in our strategy
> > > to broaden the market opportunities for zileuton,"
> > > said Paul Rubin,
> > > M.D., president and chief executive officer of
> > > Critical
> > > Therapeutics. "The focus of our Phase II trial will
> > > be to confirm
> > > the findings in that pilot study and then advance
> > > into a pivotal
> > > Phase III study."
> > >
> > > Critical Therapeutics acquired from Abbott
> > > Laboratories the
> > > worldwide rights to develop and market Zyflo for
> > > asthma. Critical
> > > Therapeutics also acquired worldwide rights to other
> > > formulations of
> > > zileuton for multiple disease and conditions
> > > including asthma, acne,
> > > chronic obstructive pulmonary disease and nasal
> > > polyps.
> > >
> > >
> > >
> > >
> > >
> > >
> > >
> > >
> > >
> > > --
> > > Please read the list highlights and FAQ before
> > > posting to the whole group (http://rosacea.ii.net).
> > >
> > > Yahoo! Groups Links
> > >
> > >
> > > rosacea-support-unsubscribe@yahoogroups.com
> > >
> > >
> > >
> > >
> > >
> > >
> >
> >
> >
> > ______________________________________________
> > Renovamos el Correo Yahoo!: ¡250 MB GRATIS!
> > Nuevos servicios, más seguridad
> > http://correo.yahoo.es